From: Childhood Hodgkin Lymphoma Treatment (PDQ®)
PDQ Cancer Information Summaries [Internet].
Bethesda (MD): National Cancer Institute (US); 2002-.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Table 8. Treatment Approaches for Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma
| Chemotherapy (No. of Cycles)a | Radiation (Gy) | No. of Patients | Event-Free Survival (No. of Years of Follow-up) | Survival (No. of Years of Follow-up) |
|---|---|---|---|---|
| COPP/ABV (4)b [23] | None | 52 | 96% (5) | 100% (5) |
| IFRT (21) | 29 | 100% (5) | ||
| CVP (3) [49] | None | 55 | 74% (5) | 100% (5) |
| DBVE (2–4)c [47] | None | 26 | 94% (8) | 100% (8) |
| IFRT (25.5) | ||||
| VAMP (4)c [53] | None | 26 | 89.4% (5) | N/A |
| IFRT (25) | 6 | 85.7% (5) | N/A | |
| VAMP (4) [45] | IFRT (15–25.5) | 33 | 100% (10) | 100% (10) |
| AV-PC [23] | None | 124 | 85.5% (5) | 100% (5) |
| IFRT (21) | 11 | |||
| Noned [24] | None | 51 | 67% (2) | 100% (2) |
IFRT = involved-field radiation therapy; N/A = not applicable; No. = number.
aRefer to Table 4 for more information about the chemotherapy regimens.
bAllocation to radiation therapy or no radiation therapy based on response to therapy.
cAllocation based on clinical response.
dAll involved lymph nodes surgically resected.